Predictive Oncology Statistics
Share Statistics
Predictive Oncology has 8.93M
shares outstanding. The number of shares has increased by 75.76%
in one year.
| Shares Outstanding | 8.93M |
| Shares Change (YoY) | 75.76% |
| Shares Change (QoQ) | 8.14% |
| Owned by Institutions (%) | 0% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 500 |
| FTD / Avg. Volume | 0.02% |
Short Selling Information
The latest short interest is 202.65K, so 2.81% of the outstanding
shares have been sold short.
| Short Interest | 202.65K |
| Short % of Shares Out | 2.81% |
| Short % of Float | 2.86% |
| Short Ratio (days to cover) | 2 |
Valuation Ratios
The PE ratio is -0.37 and the forward
PE ratio is 12.19.
Predictive Oncology's PEG ratio is
0.01.
| PE Ratio | -0.37 |
| Forward PE | 12.19 |
| PS Ratio | 2.75 |
| Forward PS | 0.3 |
| PB Ratio | -22.07 |
| P/FCF Ratio | -0.41 |
| PEG Ratio | 0.01 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Predictive Oncology.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.62,
with a Debt / Equity ratio of -10.52.
| Current Ratio | 0.62 |
| Quick Ratio | 0.51 |
| Debt / Equity | -10.52 |
| Debt / EBITDA | -0.21 |
| Debt / FCF | -0.19 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $70,600.74 |
| Profits Per Employee | $-530,489.61 |
| Employee Count | 23 |
| Asset Turnover | 0.33 |
| Inventory Turnover | 2.14 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -37.58% in the
last 52 weeks. The beta is 1.3, so Predictive Oncology's
price volatility has been higher than the market average.
| Beta | 1.3 |
| 52-Week Price Change | -37.58% |
| 50-Day Moving Average | 1.13 |
| 200-Day Moving Average | 1.02 |
| Relative Strength Index (RSI) | 42.13 |
| Average Volume (20 Days) | 2,800,018 |
Income Statement
In the last 12 months, Predictive Oncology had revenue of 1.62M
and earned -12.2M
in profits. Earnings per share was -2.32.
| Revenue | 1.62M |
| Gross Profit | 797.68K |
| Operating Income | -10.94M |
| Net Income | -12.2M |
| EBITDA | -10.16M |
| EBIT | -10.94M |
| Earnings Per Share (EPS) | -2.32 |
Full Income StatementBalance Sheet
The company has 734.67K in cash and 2.13M in
debt, giving a net cash position of -1.4M.
| Cash & Cash Equivalents | 734.67K |
| Total Debt | 2.13M |
| Net Cash | -1.4M |
| Retained Earnings | -180.43M |
| Total Assets | 5.87M |
| Working Capital | -1.12M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -10.97M
and capital expenditures -9.51K, giving a free cash flow of -10.98M.
| Operating Cash Flow | -10.97M |
| Capital Expenditures | -9.51K |
| Free Cash Flow | -10.98M |
| FCF Per Share | -2.01 |
Full Cash Flow StatementMargins
Gross margin is 49.12%, with operating and profit margins of -673.69% and -751.39%.
| Gross Margin | 49.12% |
| Operating Margin | -673.69% |
| Pretax Margin | -668.81% |
| Profit Margin | -751.39% |
| EBITDA Margin | -625.97% |
| EBIT Margin | -673.69% |
| FCF Margin | -676.44% |
